More news about AC Immune

AC Immune CEO Andrea Pfeifer awarded Prix BioAlps 2013

28.11.2013 09:25

Andrea Pfeifer, the CEO of AC Immune, was awarded with the prestigious “Prix BioAlps 2013”. The award was presented to her by Prof. Jean-Claude Badoux, former Dean of the EPFL, at the BioAlps Networking Day - Nutrition and Health – in Yverdon.

The annual award honors personalities from the life sciences industry of the Western Switzerland Region who have significantly contributed to the international reputation of the BioAlps cluster. The prize recognizes Andrea Pfeifer’s personal qualities along with the successful development of a thriving biotech company.

During her speech Andrea Pfeifer said: “I feel very much honored and personally touched to receive this recognition from the BioAlps Association, who do a great job to ensure our region remains one of the leading global centers of the life science industry. A warm thank you goes to my team at AC Immune, who tirelessly, competently and full heartedly work to realize our common dream of finding a cure for Alzheimer’s disease."

She continued “Today there are no approved therapies for Alzheimer’s disease which affects 35 million people worldwide and more than 100,000 in Switzerland, leading to an incredible burden for patients but also for their families and society. I strongly hope that we will achieve our goal of curing and preventing this disease which is one of the greatest healthcare challenges of this century. To meet this challenge, we must deploy the great brains and experiences of the world’s leading scientists, healthcare professionals and government responsibles. That is why I am dedicating the BioAlps award to all global efforts in Alzheimer’s disease research.”

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

More news about AC Immune
Please login or
register to use the
bookmark feature

Related News

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

 

By continuing to use this website you agree with our TERMS AND CONDITIONS